Last reviewed · How we verify
Varicella
At a glance
| Generic name | Varicella |
|---|---|
| Sponsor | Novartis Vaccines |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults (PHASE1, PHASE2)
- The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster (NA)
- Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia (PHASE4)
- The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster (NA)
- Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above (PHASE2)
- Transcutaneous Auricular Vagus Nerve Stimulation on Post-Herpetic Neuralgia (NA)
- Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
- Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Aged 1~12 Years: A Single-armed Bridging Clinical Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Varicella CI brief — competitive landscape report
- Varicella updates RSS · CI watch RSS
- Novartis Vaccines portfolio CI